O Shaughnessy Asset Management LLC grew its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 83.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,268 shares of the biotechnology company’s stock after purchasing an additional 50,279 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Biogen were worth $19,406,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the stock. Rothschild Investment LLC boosted its position in Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 56 shares during the period. Advisory Services Network LLC lifted its stake in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after buying an additional 68 shares during the last quarter. Davis Investment Partners LLC lifted its stake in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 71 shares during the last quarter. Optas LLC boosted its holdings in shares of Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 73 shares during the period. Finally, Parallel Advisors LLC grew its position in shares of Biogen by 1.9% during the fourth quarter. Parallel Advisors LLC now owns 4,302 shares of the biotechnology company’s stock worth $757,000 after acquiring an additional 79 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.
Analysts Set New Price Targets
Several analysts recently weighed in on BIIB shares. Argus upgraded shares of Biogen to a “hold” rating in a research report on Thursday, April 9th. Wall Street Zen upgraded shares of Biogen from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Wedbush lifted their price target on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a report on Thursday, April 30th. Guggenheim boosted their price objective on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Truist Financial decreased their price objective on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a report on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $217.26.
Biogen Stock Down 1.4%
Biogen stock opened at $192.62 on Tuesday. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The stock has a market cap of $28.44 billion, a price-to-earnings ratio of 20.67 and a beta of 0.20. The company’s 50-day moving average price is $187.63 and its two-hundred day moving average price is $183.63. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.
Biogen (NASDAQ:BIIB – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the business posted $3.02 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.
Biogen Company Profile
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
Further Reading
- Five stocks we like better than Biogen
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Free Report).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
